What is the preferred treatment option between HoLEP (Holmium Laser Enucleation of the Prostate) and UroLift for a male patient with benign prostatic hyperplasia (BPH) and significant urinary symptoms?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 14, 2026 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

HoLEP vs UroLift for BPH Treatment

HoLEP is the superior choice for most patients with BPH requiring surgical intervention, offering durable long-term outcomes, size-independent efficacy, and proven superiority over traditional gold standards like TURP. 1, 2

Guideline-Based Recommendations

HoLEP: Strongly Recommended

  • The AUA explicitly recommends HoLEP as a prostate size-independent suitable option for treatment of LUTS/BPH (Moderate Recommendation; Evidence Level: Grade B). 1
  • The European Association of Urology similarly endorses HoLEP as a size-independent treatment option with robust evidence. 1
  • HoLEP has effectively replaced TURP and open prostatectomy as the modern endoscopic gold standard for BPH treatment. 2, 3

UroLift (Prostatic Urethral Lift): Conditionally Recommended

  • The AUA recommends prostatic urethral lift (PUL/UroLift) with only a Conditional Recommendation based on lower quality evidence. 1
  • UroLift is specifically limited to patients with prostate volumes <80g, whereas HoLEP has no size restrictions. 4

Clinical Outcomes Comparison

Durability and Efficacy

  • HoLEP demonstrates sustained symptom improvement extending beyond 10 years, with one randomized trial showing superior outcomes to TURP at 7-year follow-up including better Qmax (4.36 mL/s improvement), erectile function (2.39 points improvement), and greater tissue removal (15.7 grams more). 3
  • HoLEP achieves a 200% increase in peak flow rate and 75% improvement in symptom scores at 1 year, with continued improvement during subsequent follow-up. 5
  • UroLift shows 50% improvement in IPSS sustained up to 36 months, but long-term data beyond 3 years is limited. 4

Functional Outcomes

  • HoLEP provides maximal tissue removal and objective functional outcomes, making it ideal for patients prioritizing long-term durability and low reoperation rates. 4
  • UroLift preserves ejaculatory function with significantly improved ejaculation function and bother scores at 12 and 36 months (P=0.006 and P=0.003). 4
  • Both HoLEP and UroLift preserve erectile function, with HoLEP showing no significant changes in erectile function scores compared to baseline. 1

Patient Selection Algorithm

Choose HoLEP for:

  • Any prostate size, particularly prostates >80g where UroLift is contraindicated. 1, 4
  • Patients requiring maximal tissue removal and definitive long-term treatment. 4
  • Patients on anticoagulation or antiplatelet therapy due to HoLEP's superior hemostatic properties and minimal bleeding risk. 1, 4
  • Patients prioritizing proven long-term durability (>10 years of data). 6, 3
  • Patients who can accept retrograde ejaculation as a trade-off for superior functional outcomes. 1

Consider UroLift only for:

  • Patients with confirmed prostate volume <80g. 4
  • Patients who prioritize ejaculation preservation above all other outcomes. 4
  • Patients seeking rapid recovery and willing to accept potentially inferior long-term functional outcomes. 4
  • Patients who understand the limited long-term data beyond 3 years. 4

Critical Safety Considerations

HoLEP Safety Profile

  • HoLEP is specifically recommended for patients at higher bleeding risk, including those on anticoagulation/antiplatelet therapy, with negligible transfusion rates. 1, 4
  • Transient stress incontinence occurs in 4.2% of patients and typically resolves. 5
  • Bladder neck contracture and urethral stricture each occur in only 1.3% of patients. 5
  • The learning curve exists but can be overcome with mentored or self-directed training without compromising patient safety. 6

Common Pitfalls to Avoid

  • Do not offer UroLift to patients with prostates >80g as this exceeds the evidence-supported indication. 4
  • Do not choose UroLift for patients requiring definitive long-term treatment, as reoperation rates and durability beyond 3 years remain unclear. 4
  • Do not avoid HoLEP in anticoagulated patients; this is actually an ideal indication for the procedure. 1, 4

Evidence Quality Assessment

The recommendation for HoLEP is based on Grade B evidence with moderate strength, supported by multiple randomized controlled trials, systematic reviews, and meta-analyses demonstrating superiority over TURP. 1 In contrast, UroLift carries only conditional recommendation status, reflecting lower quality evidence and shorter follow-up data. 1, 4

For the vast majority of patients with BPH requiring surgical intervention, HoLEP should be the first-line surgical option due to its size-independent efficacy, proven long-term durability, superior functional outcomes, and excellent safety profile even in high-risk patients. 1, 4, 2

References

1
Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

4
Guideline

HoLEP and Rezum for BPH Treatment

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Related Questions

What is the Holmium Laser Enucleation of the Prostate (HoLEP) procedure?
Is Holmium Laser Enucleation of the Prostate (HoLEP) effective for treating benign prostatic hyperplasia in patients with a high bladder neck?
What is the effectiveness of Holmium Laser Enucleation of the Prostate (HoLEP) for treating Benign Prostatic Hyperplasia (BPH)?
Which is more effective for treating Benign Prostatic Hyperplasia (BPH), Rezum or Holmium Laser Enucleation of the Prostate (HoLEP)?
What are the considerations for Holmium Laser Enucleation of the Prostate (HoLEP) or Robotic-assisted HoLEP for a patient with a 150g prostate and symptoms of Benign Prostatic Hyperplasia (BPH)?
What is the mortality rate for measles, particularly in young children and individuals with weakened immune systems?
What are the considerations for using Ziprasidone (Geodon) in a patient with bipolar disorder, diabetes, chronic obstructive pulmonary disease (COPD), sleep apnea, and significant disability?
What medications, such as selective serotonin reuptake inhibitors (SSRIs) like sertraline (Zoloft) or paroxetine (Paxil), beta blockers like propranolol (Inderal), or hormone therapies like estrogen replacement therapy, can cause excessive sweating as a side effect?
Does medroxyprogesterone interfere with Mounjaro (tirzepatide) in an adult patient with type 2 diabetes?
Should a 75-year-old male with a history of lacunar stroke, currently asymptomatic and with well-controlled LDL levels on Lipitor (Atorvastatin) 80mg per day, have his Lipitor dose decreased?
Can topiramate (anticonvulsant medication) cause increased anxiety, brain fog, and insomnia in a patient with a history of epilepsy or migraines, particularly when symptoms started after initiating topiramate therapy?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question